Hepcidin and Erythroferrone in the Anemia of Low-Risk Myelodysplastic Syndromes

被引：1
|
作者：
Oarbeascoa, Gillen [1 ]
Redondo, Sara [2 ]
Jose Moran-Jimenez, Maria [3 ]
Domingo, Amalia [1 ]
Munoz-Linares, Cristina [2 ]
Isabel Moreno-Carralero, Maria [4 ]
Maria Bellon, Jose [5 ]
del Campo Rincon, Juan Francisco [2 ]
Luis Diez-Martin, Jose [1 ,5 ,6 ]
Font, Patricia [1 ,5 ]
机构：
[1] Hosp Gen Univ Gregorio Maranon, Hematol Dept, Madrid, Spain
[2] Hosp Univ Henares, Hematol Dept, Madrid, Spain
[3] Hosp 12 Octubre I 12, Inst Invest Sanitaria, Madrid, Spain
[4] Hosp 12 Octubre Imas12, Inst Invest Sanitaria, Madrid, Spain
[5] Inst Invest Sanitaria Gregorio Maranon, Madrid, Spain
[6] Univ Complutense Madrid, Dept Med, Madrid, Spain
来源：
BLOOD | 2018年 / 132卷
关键词：
D O I：
10.1182/blood-2018-99-116992
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3085
引用
收藏
页数：3
相关论文
共 50 条
  • [11] Clinical responses to alemtuzumab in six patients with low-risk myelodysplastic syndromes and aplastic anemia
    Neukirchen, J.
    Strupp, C.
    Kuendgen, A.
    Tsamaloukas, A.
    Haas, R.
    Germing, U.
    ONKOLOGIE, 2012, 35 : 148 - 149
  • [12] Treatment of anemia in low-risk myelodysplastic syndromes with amifostine. In vitro testing of response
    Viniou, N
    Terpos, E
    Galanopoulos, A
    Kritikou-Griva, E
    Akel, S
    Michalis, E
    Apostolidou, E
    Georgiadou, D
    Kouraklis, A
    Parharidou, A
    Kokkini, G
    Symeonidis, A
    Anagnostopoulos, NI
    Christakis, JI
    Tasiopoulou, A
    Loukopoulos, D
    Yataganas, X
    ANNALS OF HEMATOLOGY, 2002, 81 (04) : 182 - 186
  • [13] Current treatment strategies in low-risk myelodysplastic syndromes
    Giagounidis, Aristoteles A. N.
    Germing, Ulrich
    Aul, Carlo
    CANCER TREATMENT REVIEWS, 2007, 33 : S19 - S24
  • [14] BURDEN OF DISEASE IN LOW-RISK MYELODYSPLASTIC SYNDROMES IN SPAIN
    Valcarcel, D.
    Montoro, M. J.
    Tormo, M.
    Bargay, J.
    Moreno, E.
    Aceituno, S.
    Bellmunt, A.
    Soler, M.
    Rafel, M.
    Villarrubia, R.
    VALUE IN HEALTH, 2022, 25 (12) : S155 - S156
  • [15] Survivin expression in "low-risk" and "high-risk" myelodysplastic syndromes
    Gianelli, Umberto
    Fracchiolla, Nicola Stefano
    Cortelezzi, Agostino
    Pellegrini, Caterina
    Savi, Federica
    Moro, Alessia
    Grimoldi, Maria Grazia
    Deliliers, Giorgio Lambertenghi
    Coggi, Guido
    Bosari, Silvano
    ANNALS OF HEMATOLOGY, 2007, 86 (03) : 185 - 189
  • [16] Survivin expression in “low-risk” and “high-risk” myelodysplastic syndromes
    Umberto Gianelli
    Nicola Stefano Fracchiolla
    Agostino Cortelezzi
    Caterina Pellegrini
    Federica Savi
    Alessia Moro
    Maria Grazia Grimoldi
    Giorgio Lambertenghi Deliliers
    Guido Coggi
    Silvano Bosari
    Annals of Hematology, 2007, 86 : 185 - 189
  • [17] New aspects of the treatment of patients with low-risk myelodysplastic syndromes
    Hofmann, WK
    Seipelt, G
    Kalina, U
    Hoelzer, D
    ONKOLOGIE, 2000, 23 (01): : 12 - 16
  • [18] Treatment of low-risk myelodysplastic syndromes by erythroprotein and its derivatives
    Villeval, Jean-Luc
    Sainty, Danielle
    HEMATOLOGIE, 2006, 12 : 10 - 11
  • [19] Biosimilar epoetin in elderly patients with low-risk myelodysplastic syndromes improves anemia, quality of life, and brain function
    Roberto Castelli
    Giorgio Lambertenghi Deliliers
    Riccardo Colombo
    Guido Moreo
    Paolo Gallipoli
    Giuseppe Pantaleo
    Annals of Hematology, 2014, 93 : 1523 - 1529
  • [20] Twice-Weekly High-Dose rHuEpo for the Treatment of Anemia in Patients with Low-Risk Myelodysplastic Syndromes
    Latagliata, R.
    Oliva, E. N.
    Volpicelli, P.
    Carmosino, I.
    Breccia, M.
    Vincelli, I.
    Alati, C.
    Napoleone, L.
    Vozella, F.
    Nobile, F.
    Alimena, G.
    ACTA HAEMATOLOGICA, 2008, 120 (02) : 104 - 107
12345